BioNTech, keeping its powder dry, pays WuXi $20M for 2 preclinical monoclonal antibodies

BioNTech is continuing to add to its sprawling R&D portfolio without denting its cash mountain. Chinese service provider WuXi Biologics is the latest company to feed the biotech’s appetite for assets, accepting a $20 million offer for monoclonal antibodies against two undisclosed targets.